Best Grants for Cancer Nonprofits in Guam

The National Cancer Institute's STRIPE program aims to advance cancer therapy by investigating the effects of radionuclide-emitted radiation. This initiative encourages multidisciplinary research to understand how radiation impacts normal tissues and tumor cells, ultimately improving therapeutic outcomes. By consolidating various funding mechanisms, STRIPE seeks to lower entry barriers for researchers, enhance the scientific foundation of radiopharmaceutical therapy, and foster innovative treatment strategies. Projects can be exploratory or research-focused, with flexible timelines for completion.

The NCI Worta McCaskill-Stevens Career Development Award supports new clinicians committed to research in community oncology and cancer prevention. This funding aims to facilitate their transition to independent research careers and advanced funding mechanisms. Scholars can lead independent community-based clinical trials, conduct ancillary studies, or gain valuable research experience, specifically targeting underserved communities. Applications are due by 5:00 PM local time of the applicant's organization.

The Canine Cancer Immunotherapy Network (K9CIN) aims to advance canine cancer treatments through innovative clinical trials, paralleling the development of human therapies. This initiative is vital as pet dogs naturally develop cancer, mirroring human responses to treatments. By leveraging NIH support, K9CIN will facilitate research to enhance immunotherapeutic strategies for both dogs and humans, fostering a collaborative environment for veterinary and human medical advancements. Ultimately, this funding opportunity promotes ethical research that benefits both species.

This funding opportunity aims to bolster the cancer surveillance workforce through educational initiatives. By enhancing collaborations with cancer partners and developing tools for improved data quality, this program will expand the capacity of registrars. Efforts will focus on recruitment and retention, ultimately ensuring compliance with Public Law 102-515. Strengthening the cancer registrar workforce will lead to timely and accurate cancer data submission, supporting public health objectives.

Cancer and health disparities researchers in Guam and other eligible U.S. locations can seek funding for multi-level or multi-domain interventions to reduce disparities in liver diseases and liver cancer. US Dept. of Health & Human Services: National Institutes of Health supports projects focused on improving outcomes among populations experiencing health disparities.

With a mission to advance cancer research, NIH provides Guam cancer and oncology researchers with funding up to US $1,900,000 for pre-clinical nanotechnology-based diagnostics and therapeutics. Academic or research institutions developing nanoparticle or nano-device cancer interventions that can progress toward NCI translational programs may be strong candidates.

Postdoctoral cancer researchers planning clinical trials in Guam can access funding through the National Institutes of Health’s NCI Pathway to Independence Award (K99/R00). Grants from NIH help oncology and medical training professionals transition from mentored postdoctoral roles to independent, tenure-track or equivalent research positions while building competitive cancer research programs.

The FY26 Peer Reviewed Cancer Research Program's Idea Award promotes innovative, high-risk cancer research initiatives. It supports groundbreaking concepts that advance cancer knowledge, patient care, and treatment options within the Military Health System. Projects must demonstrate creativity and innovation, avoiding incremental advancements. Notably, the Early Career Investigator Option is available to foster the growth of promising new investigators early in their careers. This award aims to make significant contributions to cancer research for Service Members and Veterans.

The DoW Peer Reviewed Cancer Clinical Trial Award supports the rapid initiation of clinical trials aimed at significantly improving cancer treatment. Projects may range from small pilot studies to large-scale phase III trials, focusing on innovative products, drugs, or devices. This award mandates the inclusion of patient advocates and prohibits animal studies, ensuring that all preclinical work is completed prior to the award start date. Regulatory applications must be submitted if required for the proposed trials.

The FY26 Peer Reviewed Cancer Research Program Impact Award promotes significant research aimed at enhancing clinical cancer care. It requires preliminary data to ensure feasibility and emphasizes projects with a strong potential for immediate impact. This funding supports clinical trials and allows for either a single Principal Investigator or a duo of partnering PIs, ensuring that both can contribute distinct aspects of the research. Applications must be carefully coordinated to avoid withdrawal risks.

The NCI Research Specialist Award (R50) supports clinician scientists involved in NCI-funded clinical trials. This funding opportunity encourages the development of stable research careers by providing salary support and autonomy, allowing clinician scientists to contribute to national clinical trial development and implementation. They play a critical role in sustaining the NCI clinical trials network without serving as principal investigators. This award aims to ensure continuity in cancer research careers.

The NCI Research Specialist Award (R50) supports non-tenure track scientists in cancer research who provide essential contributions within laboratories and core facilities. This award aims to enhance research careers for skilled scientists who do not seek independent investigator funding. Eligible candidates must possess an advanced degree, have at least two years of contribution to NCI-funded research, and dedicate a significant portion of their time to this work. The R50 offers salary support and travel funds to recognize and stabilize these vital roles in cancer research.

The Radiation Oncology-Biology Integration Network (ROBIN) Centers, funded by the National Cancer Institute (NCI), aims to enhance national radiation oncology infrastructure through collaborative research. This initiative supports studies on biological responses to radiation treatment in cancer patients, focusing on understanding tumor and tissue changes. By integrating various scientific disciplines and collecting comprehensive data, ROBIN intends to improve cancer care, optimize treatment strategies, and accelerate translational discoveries to enhance patient outcomes.

The Paul Calabresi Career Development Award for Clinical Oncology aims to enhance the training of clinician-scientists in clinical and translational cancer research. This funding opportunity encourages the career growth of researchers but does not permit Scholars to lead independent clinical trials. Instead, it allows participation in clinical trials under the mentorship of an experienced researcher, fostering a collaborative approach to cancer research.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers transitioning to independent faculty positions. This funding opportunity encourages talented individuals with clinical or research doctoral degrees to lead independent clinical trials. Applicants should aim to foster research careers in cancer control, prevention, and data sciences. This initiative provides essential support during the transition from mentored positions to independent research roles, enhancing the pool of independent investigators in cancer research.

The NCI Pathway to Independence Award (K99/R00) supports early-stage postdoctoral researchers aiming to transition to independent faculty positions. It encourages candidates with doctoral degrees in research or clinical fields to apply, particularly those in cancer control and prevention. This funding opportunity facilitates a quick shift from mentored research to independent careers, providing essential support for awardees to establish competitive research programs without leading their own clinical trials.

The National Cancer Institute invites applications for the validation of biomarkers and assays for cancer detection and treatment. This funding opportunity supports both analytical and clinical validation of assays, emphasizing the importance of human samples. The program encourages multi-disciplinary collaboration and aims to enhance the performance and reproducibility of cancer assays across clinical laboratories. Applications are due by 5:00 PM local time during the designated deadlines each year.

The Exploratory Grant Award aims to enhance workforce diversity in basic cancer research by supporting junior and Early Stage Investigators from underrepresented groups in the biomedical and social sciences. This initiative provides essential funding to bridge the gap for researchers completing their training, ensuring they have the resources needed to develop larger grant applications. Applications are due by 5:00 PM local time of the applicant organization, emphasizing the importance of timely submissions.

The DoW Rare Cancers Concept Award for FY26 promotes groundbreaking ideas in rare cancer research. This award encourages innovative applications that explore novel courses of investigation without requiring preliminary data. Unique to this program is the prohibition against mentioning the Principal Investigator or collaborators in the proposal materials, ensuring an unbiased review process. This funding opportunity aims to advance scientific discovery in the rare cancer domain.

Cancer research institutions and translational research centers working on human cancer can seek funding to advance prevention, early detection, diagnosis, and treatment in Guam and other U.S. territories. The National Cancer Institute’s SPORE P50 program offers US $25,000,000 for state-of-the-art, organ-specific or mechanism-based translational cancer research with clear human endpoints.

Research institutions and similar organizations studying tobacco, alcohol, or cannabis policies and their effects on health can apply for funding up to US $275,000 from the National Institutes of Health. Grants from NIH help Guam cancer and health equity researchers partner with community organizations to examine policy impacts on substance use, exposure, and cancer prevention among populations experiencing disparities.

Research institutions and universities in Guam working on cancer and biomedical imaging can access funding through the National Institutes of Health to develop molecular imaging methods for studying inflammation in cancer in vivo. Awards up to US $2,500,000 support integrated pre-clinical and clinical imaging research and cross-field collaboration between cancer scientists and imaging experts.

Cancer research institutions and clinical teams in Guam and other eligible U.S. territories can seek funding to integrate imaging and liquid biopsy tumor monitoring during cancer therapy. Focused on advancing cancer/oncology and biomedical imaging, the National Institutes of Health supports R01 projects that optimize these modalities for assessing treatment response and emerging resistance, with awards up to US $2,500,000.

Research institutions and similar organizations studying tobacco, alcohol, or cannabis policy impacts on cancer-related health equity can apply for up to US $2,500,000 in Guam and across the U.S. NIH provides Guam cancer and health disparities researchers with funding to evaluate policies, engage community partners, and reduce exposure among populations experiencing disparities.

Nonprofit and research organizations developing cancer biomarker assays for detection, diagnosis, prognosis, or treatment response can apply for up to US $275,000 from the National Institutes of Health, including projects in Guam. With a mission to advance cancer research, NIH supports analytical (UH2) and clinical (UH3) validation of high-quality assays using human samples.

Cancer research institutions and clinical laboratories in Guam working on biomarker assays for cancer detection, diagnosis, or treatment response can access funding through the National Institutes of Health. Awards up to US $750,000 support clinical validation of analytically validated molecular, cellular, or imaging markers and harmonization of assay performance across studies and laboratories.

Guam cancer and health-disparities research organizations can access funding through the National Institutes of Health to test clinical trials that expand cancer screening and preventive services. Projects must address barriers and facilitators to screening and follow-up in populations experiencing health disparities, working at multiple levels and in collaboration with community partners and healthcare providers.